(Editor’s Note: John Quintner, MD, is a rheumatologist and pain medicine specialist in Australia who recently retired from clinical practice. He has published numerous articles on chronic pain in Pain Medicine, Clinical Journal of Pain, The Lancet and other medical journals.)
The latest fads from the shadowy world of pseudo-science have always been quick to take off. For those who are keen on approaching pain sufferers with their sharp needles, the invention of Neural Prolotherapy by Dr. John Lyftogt, of Christchurch in New Zealand, must have come as a godsend.
In theory, Neural Prolotherapy is the injection of sugar (glucose) just below the skin to promote the healing of nerves and tissues damaged by neuropathy, sports injuries and other types of chronic pain conditions. “Prolo” is short for proliferation and derives from the Latin “to regenerate or rebuild”.
A quick search on the Internet reveals that Neural Prolotherapy is being taken seriously by a number of health practitioners who one might have expected to have known better than to accept it so uncritically.
Prolotherapy with injectable substances (such as autologous platelet rich plasma, autologous blood, and bone marrow aspirate) acclaimed as growth factors is now the subject of intensive research.
But Dr. Lyftogt favors hypertonic sugar injections.
Here are some remarkable extracts from his website:
“After the success of Neural Prolotherapy with Achilles tendonitis other persistent painful conditions of the neck, back, shoulders, elbows, wrists, knees, ankles and feet have been effectively treated by targeting the local inflamed superficial nerves with micro-injections of low dose Glucose.”
My Comment: there have been no properly conducted clinical trials of Neural Prolotherapy.
“More recently Dr. Lyftogt has developed effective neural prolotherapy treatment protocols for Migraine, Fibromyalgia, CRPS, compartment syndrome and other difficult to treat persistent painful conditions.”
My Comment: Again, no clinical trials have been conducted. The evidence is purely anecdotal and subject to all forms of bias.
“Neural prolotherapy is an effective novel and evolving treatment for non-malignant persistent pain, based on sound neuroscientific principles.”
“Subcutaneous prolotherapy with a series of percutaneous near nerve injections has been shown to be an effective treatment for a variety of recalcitrant painful conditions caused by prolonged neurogenic inflammation.”
My Comment: This is the logical fallacy called circular argument: the conclusion is assumed before the evidence is presented. Dr. Lyftogt offers no evidence that these conditions are associated with “prolonged neurogenic inflammation”.
Dr. Lyftogt targets the “guilty” superficial nerves by injecting 5% Mannitol or 5% dextrose and thereby claims to modulate the neurogenic inflammation that he believes is responsible for neuropathic pain. He refers to the work of a highly regarded authority:
“Quintessential to the working hypothesis that subcutaneous prolotherapy treats prolonged pathological neurogenic inflammation is the work by Douglas W. Zochodne from the Neuroscientific Research Unit at Calgary University.” 
When contacted by the author, Professor Zochodne replied: “I can indicate that I have no interest in it, have not endorsed it or plan to endorse it and am disappointed our work would be quoted for something without evidence.”
But there is more!
“(Dr. Lyftogt) hypothesizes that subcutaneous prolotherapy injections of hypertonic glucose and 0.1% lignocaine induce apoptosis of proliferating peptidergic noceffectors (i.e. SP and CGRP) and neovessels by reducing VEGF (vascular endothelial growth factor) levels and restoring ‘effective repair processes’ with reduction of pain.” 
My Comment: In this author’s opinion, this is pure speculation.
On his website and in a recent email to Associate Professor Geoff Bove, a world leader in experimental studies of nervi nervorum (“the nerves of the nerves”), Dr. Lyftogt claims that his injections target specific receptors (TRPV1) present on the nervi nervorum.
“The very small nerve fibers, innervating the nerve trunk, identified as unmyelinated C-fibers or ‘Nervi Nervorum’ are responsible for pain and swelling of the protective sheath of the nerve trunk. This was already demonstrated 125 years ago by Professor John Marshall from London and called neuralgia. It is now called ‘neurogenic inflammation’.”
My Comment: Dr. Marshall was in fact advocating “nerve stretching” in his Bradshaw Lecture given in London. Fortunately, this form of treatment has long been abandoned as being both ineffective and potentially dangerous.
Dr. Bove made the following personal response to Dr. Lyftogt in relation to his facile incrimination of the nervi nervorum:
“Dextrose does not do anything to TRPV1 receptors, and it is certainly not selective for abnormal ones (and there is no knowledge that those exist). You are not targeting nervi nervorum other than in your mind; they are few and far between on the small peripheral nerves, and maybe nonexistent.
Regardless, you have nothing to offer regarding the injected dextrose reducing their function and thus reducing neurogenic inflammation, or reducing neurogenic inflammation at all.”
The Bottom Line
According to Dr Lyftogt: “The growing scientific evidence supporting the view that neuropathic pain syndromes are caused by unremitting peripheral neurogenic inflammation involving the autonomic and sensory nerves may lead to renewed interest in prolotherapy and neural therapy as these treatments are effective and seem to target the PNS.” 
However, Dr. Lyftogt has yet to demonstrate the presence of the unremitting (enhanced) neurogenic inflammation that he claims to have identified and treated with his sugar injections.
The question as to the efficacy of Neural Prolotherapy, as practiced and taught around the world by Dr. Lyftogt, is outside the scope of this article. There are no published trials upon which to base any firm conclusions.
Anecdotally, there may be face validity for this treatment but to date there has been no discussion of placebo effect, observer bias, expectation bias, or reversion to the mean of the conditions being treated.
But what is abundantly clear is that published animal experimental research by leading neurobiologists Professor Douglas Zochodne and Associate Professor Geoffrey Bove does NOT in any way support Dr. Lyftogt’s hypothesis. This should be the end of the story, but I suspect that the aphorism by Francis Bacon is as true today as it was over 400 years ago:
“The human understanding when it has once adopted an opinion draws all things else to support and agree with it. And though there be a greater number and weight of instances to be found on the other side, yet these it either neglects or despises, or else – by some distinction sets aside and rejects, in order that by this great and pernicious determination the authority of its former conclusion may remain inviolate” — Francis Bacon (1620)
All we can do is hope that good science will triumph over its rival.
1. Lyftogt J. Subcutaneous prolotherapy treatment of refractory knee, shoulder and lateral elbow pain. Australasian Musculoskeletal Medicine November, 2007: 83-85.
2. Lyftogt J. Prolotherapy for recalcitrant lumbago. Australasian Musculoskeletal Medicine May 2008: 18-20.
3. Lyftogt J. Pain conundrums: which hypothesis? Australasian Musculoskeletal Medicine November 2008: 72-7
The information in this column is not intended to be considered as professional medical advice, diagnosis or treatment. Only your doctor can do that! It is for informational purposes only and represents the author’s personal experiences and opinions alone. It does not inherently or expressly reflect the views, opinions and/or positions of National Pain Report or Microcast Media.
National Pain Report welcomes opposing opinions on this and other topics.